Replies to post #245010 on Biotech Values

[bladerunner1717]

re: APGN

Looks interesting. Up 80% inn pre-Market


EF Hutton analyst Tony Butler initiated coverage of Apexigen with a Buy rating and $8 price target. The "recently de-SPACed" biotech is developing sotigalimab as an orthogonal immunoactivating therapy in combination with immune checkpoint inhibitors and chemotherapy against a number of cancer indications, Butler tells investors.

Bladerunner

[DewDiligence]

APGN—(-19%)—reduces workforce 55%:

https://finance.yahoo.com/news/apexigen-announces-review-strategic-alternatives-130000299.html

The 55% layoff comprises 11 of the 20 employees, based on APGN’s prior SEC filings.